ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / KTTA / earnings
BIVI (32) RKTO (40) HIND (29) JAGX (28) ⌘ Pro Terminal →

Pasithea Therapeutics Corp. (KTTA) Next Earnings Date & Expected ±12.5% Move

$0.37 -0.59% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.37

Pasithea Therapeutics Corp. (KTTA) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $12.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KTTA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KTTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Pasithea Therapeutics Corp. (NASDAQ: KTTA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $0.37 (-0.59% 1D, market cap $12.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, KTTA ranks #472 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KTTA compare to BIVI and RKTO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KTTA carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BIVI (BioVie Inc. (Class A)) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $12.4M) and RKTO (Rocket One Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $12.1M). Among the 5-stock peer group, KTTA leads on earnings multiple (N/A) while KTTA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KTTA?
▼

Per KTTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001841330), Pasithea Therapeutics Corp. generated $58.4M in revenue (+46.4% YoY), -$20.4M in net income, and -$15.2M in free cash flow against $60.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.37 (-0.30%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510040
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (8)Whales (8)SEC (10)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-8.1% Base Target
$2 Bull$0 Base$0 Bear
📬 FREE KTTA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KTTA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (40/100 Composite)
🔍 WHY KTTA SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (23% of score)

FRED Regime × Technicals: 5% of 52W Range • RSI-14 at 34.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
48
Grade D$0.42-2.4% Next Q
Q2 (-2Q)
45
Grade D$0.41-2.4% Next Q
Q3 (-1Q)
43
Grade D$0.40-7.5% Next Q
Current
40
Grade D-$0.37-7.4% Hist 90D α
Trajectory: D (48) → D- (40)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KTTA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KTTA currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.48) and Max Pain ($0.39) forces dealer call-delta covering toward $2.16.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KTTA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “KTTA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 40%NO 60%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.05 Expected Swing
$1.00 (-12.5%)Spot $0.37$0.42 (+12.5%)
MODEL EARNINGS SETUP GAUGE

KTTA Quantitative Pre-Earnings Setup: 40/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (40/100)Model Risk Weight (60/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$58.4M-$20.4M-$15.2M52%
FY 20242024-12-31$39.9M-$13.9M-$13.9M52%
FY 20232023-12-31$44.7M-$16.0M-$14.4M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KTTA)

  • ✓Walkthrough of KTTA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
KTTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -56.47%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.37H $0.37L $0.37C $0.37VOL 100.2K
RES: $0.48SUP: $0.33SMA50: $0.48SMA200: $0.63
$1.00$0.82$0.64$0.46$0.28RES $0.48SUP $0.33$0.372026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KTTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KTTA Butterfly Map → + Track KTTA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +46.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on KTTA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KTTA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KTTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KTTA)

Health Care Rank #472 of 1015 ⚔️ BIVI vs KTTA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KTTA vs. BIVI, RKTO, HIND, JAGX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Pasithea Therapeutics Corp. (KTTA) ranks #472 by composite RQD confidence (40/100, grade D-) and #874 by equity capitalization ($12.4M). Within this direct 5-issuer industry benchmark cohort, KTTA leads on earnings valuation at N/A trailing P/E, while KTTA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. KTTA currently leads its immediate peer cohort in composite quantitative strength at 40/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
KTTA ACTIVE
Pasithea Therapeutics Corp.
D- 40/100 — — -35.0% -0.59% $12.4M Benchmark Subject
BIVI
BioVie Inc. (Class A)
E 32/100 — — -35.0% -4.20% $12.4M /bivi-vs-ktta →
RKTO
Rocket One Inc.
D- 40/100 — — -35.0% -7.68% $12.1M /rkto-vs-ktta →
HIND
Vyome Holdings Inc.
E 29/100 — 68.4% -35.0% -2.22% $12.6M /hind-vs-ktta →
JAGX
Jaguar Health Inc.
E 28/100 — 67.2% -35.0% -45.43% $12.6M /jagx-vs-ktta →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001841330 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pasithea Therapeutics Corp. (KTTA) reported GAAP revenue of $58.4M (+46.4% vs. FY2024 revenue of $39.9M , and +30.5% cumulative change since FY2023) , GAAP net income of -$20.4M, operating cash flow of -$15.2M, and free cash flow of -$15.2M (-9.3% YoY). On the balance sheet, KTTA closed FY2025 with $60.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $58.4M -$20.4M -$15.2M -$15.2M $60.2M —
FY2024 (FY) 2024-12-31 $39.9M -$13.9M -$13.9M -$13.9M $16.1M —
FY2023 (FY) 2023-12-31 $44.7M -$16.0M — — — —

3. KTTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KTTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Pasithea Therapeutics Corp. (NASDAQ: KTTA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $0.37 (-0.59% 1D, market cap $12.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, KTTA ranks #472 in composite RQD confidence.

How does KTTA compare to BIVI and RKTO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KTTA carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BIVI (BioVie Inc. (Class A)) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $12.4M) and RKTO (Rocket One Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $12.1M). Among the 5-stock peer group, KTTA leads on earnings multiple (N/A) while KTTA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KTTA?

Per KTTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001841330), Pasithea Therapeutics Corp. generated $58.4M in revenue (+46.4% YoY), -$20.4M in net income, and -$15.2M in free cash flow against $60.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KTTA trading relative to its 50-day, 200-day, and 52-week technical levels?

KTTA last traded at $0.37 (-0.59% on volume of 247,650 shares), positioning the stock -22.92% below its 50-day simple moving average ($0.48) and -41.27% below its 200-day simple moving average ($0.63). Across its 52-week range of $0.28 to $2.06, KTTA sits at the 5.1% percentile with a 14-day RSI of 34.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.42).

Direct Sub-Reports: KTTA RQD Cockpit KTTA 12M Forecast KTTA Earnings & Move KTTA Dividends & DRIP KTTA Insiders & 13F KTTA Whale Options KTTA Profit Sankey KTTA News & Why
ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ SEC XBRL & RQD VERIFIED

KTTA — Pasithea Therapeutics Corp.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Pasithea Therapeutics Corp. (KTTA) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.37 (-0.59% 1D, market capitalization $12.4M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Pasithea Therapeutics Corp. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The issuer's revenue in the reported periods is —, indicating no reported product or service revenue in the source data. — for specific products, customers, or monetization model beyond clinical-stage activity referenced in news headlines.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Pasithea Therapeutics Corp. (KTTA) reported $58.4M in annual revenue (up from $39.9M in FY2024, +46.4% YoY) and -$20.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($44.7M revenue, -$16.0M net income) through FY2025, KTTA scaled operating cash flow to -$15.2M and free cash flow to -$15.2M, backed by $60.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 40/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 8/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $0.28 – $2.06 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— for upstream suppliers, downstream customers, or sector correlations beyond the sector and industry classification. A prospective investor should note that the absence of mapped dependencies means second-order effects cannot be assessed from this dataset.

  • Key Question #1: Can KTTA sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $58.4M and free cash flow of -$15.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is KTTA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

KTTA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Pasithea Therapeutics Corp. (KTTA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KTTA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KTTA Bull vs. Bear Conversation Board — What's Your Call at $0.37?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KTTA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on KTTA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $0.45 (+21.6%)
📌 Pinned Debate

Reported cash rose to $55.2M in FY 2025 from $6.9M in FY 2024 while the stock trades near its 52-week low of $0.28, with positive PAS-0

Picked up a starter position in KTTA in my $100K Virtual Cash book at $0.37. Reported cash rose to $55.2M in FY 2025 from $6.9M in FY 2024 while the stock trades near its 52-week low of $0.28, with positive PAS-004 clinical data headlines in the news wire.. Trading inside a $0.28–$2.06 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

VolSurface_Trader 🐂 BULL

@RedlineAuditor Shorting a 8/20 institutional whale-flow stock at $0.37 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $0.29 (-21.6%)
Spot @ $0.37

The company reports $0.0M revenue, FY 2025 net loss of -$20.4M, FCF of -$15.2M, ROIC of -35%, and a Piotroski F-Score of 2/9.

The company reports $0.0M revenue, FY 2025 net loss of -$20.4M, FCF of -$15.2M, ROIC of -35%, and a Piotroski F-Score of 2/9.. Look at the math on KTTA: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $0.33 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%